Trials / Terminated
TerminatedNCT00787137
Single Dose PG102 in Patients With Active Psoriatic Arthritis
A Randomised, Double Blind, Placebo Controlled, Single Ascending Dose, Phase I Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PG102 (Anti-CD40 Monoclonal Antibody) In Patients With Active Psoriatic Arthritis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- PanGenetics UK Limited · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to evaluate the safety and tolerability of a single intravenous dose of PG102 in patients with psoriatic arthritis. The secondary objectives are to evaluate how PG102 moves around the body and to explore its effects on the disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PG102 | A single intravenous infusion |
| DRUG | Placebo comparator | Phosphate-buffered saline |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2010-04-01
- Completion
- 2010-05-01
- First posted
- 2008-11-07
- Last updated
- 2010-10-26
- Results posted
- 2010-10-15
Locations
1 site across 1 country: Serbia
Source: ClinicalTrials.gov record NCT00787137. Inclusion in this directory is not an endorsement.